TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01330134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: 2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: 1% lidocaine subcutaneous injection alone
Study: NCT03919279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tVNS
Description: tVNS using TENS device from Schwa-Medico (TENSeco2) + auricular electrode applied on the left ear (Schwa-Medico) + conductive gel class I; 25 Hz stimulation 1 hour daily for 1 month
Study: NCT04286087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neck incisions closed at bedside at the time of drain removal under local anesthesia
Description: Participants allocated to the investigational group will have neck incisions closed at bedside at the time of drain removal under local anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: Participants in the control group will have standard treatment performed as per current practice,their incision will be left to close by secondary intention
Study: NCT01606267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health systems intervention: HEP+ICCM
Description: In the HEP+ICCM intervention areas, HEWs will assess and treat childhood pneumonia with cotrimoxazole. The program will strengthen the capacity of HEWs to assess, classify and treat malaria (with ACTs), diarrhea (with ORS) and undernutrition (with therapeutic feeding) through refresher trainings and strengthening supervision, logistical support and the ICCM system overall.
Study: NCT00574145

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bio-field energy therapy
Description: Practitioner's hands to influence the human energy field surrounding the patient's body.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: fatigue assessment and management
Description: duration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fatigue assessment and management
Description: duration

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: psychosocial assessment and care
Description: duration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: duration

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: quality-of-life assessment
Description: duration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: duration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic touch
Description: Practitioner's hands to influence the human energy field surrounding the patient's body
Study: NCT00866450

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Western style diet (high fat and low in calcium)
Description: Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prudent-style diet (low fat and high in calcium)
Description: Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
Study: NCT02198625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate FiO2 and Protective Lung Ventilation Using

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate FiO2 and Protective Lung Ventilation Using

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate FiO2 and Protective Lung Ventilation Using
Study: NCT01095406

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S1 ventilation
Description: Ventilation with a O2 and CO2 controller
Study: NCT02869282

Intervention type: OTHER
Intervention: Blood samples
Description: Additional blood samples at baseline, 6, 12, 18 and 24 months.

Intervention type: OTHER
Intervention: Urine samples
Description: Additional urine samples at baseline, 6, 12, 18 and 24 months.
Study: NCT01815047

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 Supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 Supplementation
Study: NCT02737852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trojan Chameleon Personal Lubricant
Description: silicone base with sensate
Study: NCT02055651

Intervention type: BEHAVIORAL
Intervention: Examination and survey
Description: Routine medical examination as required by law and follow-up for lifestyle change program
Study: NCT02088112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 IV Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 IV Q2W
Study: NCT00665873

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PORT-A-CATH (Smiths Medical Inc., MN)
Description: Port a Cath implanted by surgical cut-down

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PORT-A-CATH (Smiths Medical Inc., MN)
Description: Port a Cath implanted by surgical cut-down

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin and clavulanic acid
Description: 1 gr i.v. before the procedure
Study: NCT03805945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine group
Description: After the fetus was delivered, low-dose dexmedetomidine intraoperative infusion, postoperative low-dose dexmedetomidine patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: After the fetus was delivered, saline intraoperative infusion, postoperative patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min) without dexmedetomidine.
Study: NCT02154360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days
Study: NCT04193020

Intervention type: OTHER
Intervention: Surveillance card
Description: Surveillance card and additional examination to find novel markers and better assess the existing ones

Intervention type: OTHER
Intervention: Surveillance card
Description: Surveillance card and additional examination to find novel markers and better assess the existing ones

Intervention type: OTHER
Intervention: Surveillance card
Description: Surveillance card and additional examination to find novel markers and better assess the existing ones
Study: NCT04041089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recognition of objects
Description: * Name of shapes / colors / images / objects~* Classification of shapes / colors / images / objects

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Location of objects
Description: * Search for frequent/rarse targets among distractors sharing one or more characteristics with the target~* Hit/catch a stationary/mobile target as quickly as possible

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manipulation of objects
Description: * Storage of shapes/objects~* Use of everyday objects (pen, cutlery, etc.)
Study: NCT02839408

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus SP1
Description: Sachet containing Lactobacillus rhamnosus SP1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Tablet containing 500mg Azithromicyn

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Talc powder
Description: Sachet containing talc powder and tablet containing talc powder

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment Scaling and root planning

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment Scaling and root planning

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Periodontal treatment Scaling and root planning
Study: NCT00399789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perifosine
Description: Perifosine will be tested in 3 dose forms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perifosine
Description: Perifosine will be tested in 3 dose forms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perifosine
Description: Perifosine will be tested in 3 dose forms
Study: NCT02462356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uniportal VATS
Description: Uniportal VATS lobectomy and lymph node dissection will be performed in this group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional VATS
Description: Conventional VATS lobectomy and lymph node dissection will be performed in this group
Study: NCT02225470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389 (Eribulin Mesylate)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine injection
Study: NCT03335163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate - Participants will undergo a 6 week titrated regimen of oral topiramate to reach a maximum dose of 400mg per day:~Week 1 - topiramate PO 25mg daily Week 2 - topiramate PO 25mg twice daily Week 3 - topiramate PO 50mg twice daily Week 4 - topiramate PO 100mg twice daily Week 5 - topiramate PO 150mg twice daily Week 6 - topiramate PO 200mg twice daily
Study: NCT03251742

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hayek RTX ventilator
Description: Negative pressure ventilation in Fontan patients.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Hayek RTX ventilator
Description: Negative pressure ventilation in Fontan patients.
Study: NCT01131533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Description: vitrectomy following intravitreal erythropoietin
Study: NCT00003281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01361243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NOURISH+
Description: 6 week face-to-face parent intervention.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wellness Group
Description: 1 week face-to-face family group followed by 6 informational mailings on childhood overweight and obesity.
Study: NCT01156272

Intervention type: DEVICE
Intervention: ATS Medical 3f® Aortic Bioprosthesis, Model 1000 19mm
Description: Replacement aortic heart valve
Study: NCT03286062

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Agent VM110 and laproscopic infra-red probe
Description: Patients with evidence of persistent or recurrent ovarian/ pancreatic cancer would be injected with escalating dose of VM110 24 hr prior to laproscopic surgery to collect biopsy sample in white light and by visualizing the cancerous mass using the laproscopic infra red probe
Study: NCT00847145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1a - rMenB+OMV NZ and routine vaccines
Description: One dose of rMenB vaccine and routine vaccine at study month 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1b - rMenB+OMV NZ and routine vaccines
Description: One dose of rMenB vaccine at study month 12 and routine vaccine at study month 13.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2a - Routine and rMenB+OMV NZ vaccines
Description: One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2b - rMenB+OMV NZ and routine vaccines
Description: Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3a - rMenB+OMV NZ and routine vaccines
Description: One dose of rMenB vaccine and one dose of routine vaccine at study month 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations
Description: One dose of rMenB vaccine at study month 12 and one dose of routine vaccine study month 13.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4a- rMenB+OMV NZ and routine vaccines
Description: One dose of rMenB vaccine and one dose of routine vaccine at study month 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4b - rMenB+OMV NZ and routine vaccines
Description: One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
Study: NCT01458912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Respimat
Description: 2 puffs a.m. via Respimat inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Respimat
Description: 2 puffs a.m. via Respimat inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903 MD
Description: 2 puffs MD b.i.d. via Respimat inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903 HD
Description: 2 puffs HD p.m. via Respimat inhaler
Study: NCT02623127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study: NCT03040440

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cylindrical endotracheal tube
Description: Cylindrical endotracheal tube was intubated

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TaperGaurd endotracheal tube
Description: TaperGaurd endotracheal tube was intubated
Study: NCT02834221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided puncture
Description: A 7 megahertz ultrasound linear probe will be used.

Intervention type: OTHER
Group type: OTHER
Intervention: Anatomical landmark guided puncture
Description: Anatomical landmark puncture
Study: NCT00836628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Study: NCT02339909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed financial incentive
Description: Participants receiving the fixed financial incentive intervention will be sent a screening appointment letter offering them a fixed amount of £10 if they attend their screening appointment.
Study: NCT04672278

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Shanzha Fruit drink or placebo drink
Description: The dosage of Shanzha fruit drink or the placebo is 3 cans per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Shanzha Fruit drink or placebo drink
Description: The dosage of Shanzha fruit drink or the placebo is 3 cans per day
Study: NCT03018652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
Study: NCT00740649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSD-016
Study: NCT02339909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Probabilistic financial incentive
Description: Participants receiving the probabilistic financial incentive intervention will be sent a screening appointment letter offering them an entry into a lottery with at least a 1 in 100 chance of winning £1000 if they attend their screening appointment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants receiving the active comparator, (i.e. control) intervention, will be sent the standard diabetic retinopathy screening appointment letter.
Study: NCT01088126

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency catheter ablation
Description: radiofrequency catheter ablation, NavX system
Study: NCT00740649

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Study: NCT03921957

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiotherapy
Description: first level : W1 : 3 fractions - W2 : 2 fractions - W3 : 3 fractions second level : W1 3 fractions - W2 : 3 fractions - W3 : 3 fractions Third level : W1 : 4 fractions - W2 : 2 fractions - W3 : 2 fractions Fourth level : W1 : 4 fractions - W2 : 4 fractions
Study: NCT03883607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor 80mg
Description: Once daily oral intake of elafibranor 80 mg during 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor 120mg
Description: Once daily oral intake of elafibranor 120 mg during 3 months
Study: NCT00368953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yukon Choice stent system
Description: coronary stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Liberté stent system
Description: coronary stent implantation
Study: NCT04511559

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating Tumor DNA Methylation Sequencing
Description: Whole blood collection through venipuncture. DNA methylation levels by deep sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating Tumor DNA Methylation Sequencing
Description: Whole blood collection through venipuncture. DNA methylation levels by deep sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating Tumor DNA Methylation Sequencing
Description: Whole blood collection through venipuncture. DNA methylation levels by deep sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: tissue DNA Methylation Sequencing
Description: Isolate DNA from tissue samples from subjects. DNA methylation levels by deep sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: tissue DNA Methylation Sequencing
Description: Isolate DNA from tissue samples from subjects. DNA methylation levels by deep sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: tissue DNA Methylation Sequencing
Description: Isolate DNA from tissue samples from subjects. DNA methylation levels by deep sequencing.
Study: NCT03761433

Intervention type: DEVICE
Intervention: SPI group
Description: All patients applied surgical pleth index at the time of surgical incision, under End tidal Sevoflurane 3%
Study: NCT00635778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered as an IV infusion over one to two hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered as an IV infusion over one to two hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered as an IV infusion over one to two hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered as an IV infusion over one to two hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered as an IV infusion over one to two hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered as an IV infusion over one to two hours
Study: NCT03366896

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Malay 3D-CAM diagnostic tool 1
Description: Assessor 1 uses Malay 3D-CAM to detect Delirium

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Malay 3D-CAM Diagnostic tool 2
Description: Assessor 2 uses Malay 3D-CAM to detect Delirium
Study: NCT00635778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: Administered as an IV infusion over one to two hours
Study: NCT05893550

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smartfish Omega
Description: Fruit juice drink containing Omega-3: the experimental condition
Study: NCT00148317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: During Induction Phase (6 cycles): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 During 21-day mobilization cycle (1 cycle): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: During Induction Phase (6 cycles): dexamethasone 40 mg on days 1-4, 8-11, and 15-18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: If patients achieve less then a PR during the induction phase after 2 cycles, or less then a CR after 4 cycles: Liposomal doxorubicin was added at 30 mg/m2 on day 4 for the remaining cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophoshamide
Description: During the 21 day mobilization phase (1 cycle): cyclophosphamide at 3 g/m2 on day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: During the 21 day mobilization phase (1 cycle): 10 μg/kg/day for 10 consecutive days starting 24 hours after cyclophosphamide administration on day 9
Study: NCT04273737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine Hydrochloride
Description: 6-week long daily regimen of amantadine, twice a day, while documenting perceived effects in a diary.
Study: NCT02472470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Participants will receive 10 active TBS rTMS sessions once daily on weekdays for 2 weeks.
Study: NCT02693366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow stem cell
Description: Endovascular infusion of bone marrow derived cells in both renal arteries.
Study: NCT05893550

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smartfish Omega
Description: Fruit juice drink containing Omega-3: the experimental condition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smartfish Fruit Juice Only
Description: this is a fruit juice drink with no omega-3 added. it is the placebo condition

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Smartfish Fruit Juice Only
Description: this is a fruit juice drink with no omega-3 added. it is the placebo condition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smartfish Fruit Juice Only
Description: this is a fruit juice drink with no omega-3 added. it is the placebo condition
Study: NCT01817556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stillen Tab.